The Latin America, Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market would witness market growth of 9.4% CAGR during the forecast period (2021-2027).
In benign prostate hyperplasia therapeutics, the concept of combination therapy is rapidly becoming popular among healthcare staff and patients. A combination therapy is the integration of two or multiple drugs that are prescribed to be consumed at the same time. In addition, the combinations of drugs that come under prostate enlargement therapeutics are designed in alignment of the requirements of particular patients. This is why combination drugs are also called personalized medicines.
Moreover, the most common treatment that is widely being utilized in benign prostate hyperplasia therapeutics is the trans-urethral resection of the prostate, or also called TURP. TURP is a therapy, in which a rigid instrument is inserted in the urethra of the patient in order to diagnose the prostate enlargement. The patient is usually given anesthesia before the procedure. Moreover, transurethral resection of the prostate is a minimally invasive surgery allows no cuts on the patients’ prostate.
LAMEA is a pool of opportunities for the therapeutics industry of benign prostatic hyperplasia. Countries like South Africa and Syria are recording a high number of health-related issues that are being caused due to the substantial presence of benign prostatic hyperplasia. These issues, when combined with weaker healthcare infrastructure and facilities of countries across the region, are subject matters that require major concern.
The Brazil market dominated the LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $125 million by 2027. The Argentina market is anticipated to grow a CAGR of 10% during (2021 - 2027). Additionally, The UAE market would exhibit a CAGR of 9.1% during (2021 - 2027).
Based on Therapy, the market is segmented into Mono Drug Therapy and Combination Drug Therapy. Based on Therapeutics Class, the market is segmented into Alpha Blockers, 5- alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Benign Prostatic Hyperplasia Therapeutics Market is Predict to reach $7.4 Billion by 2027, at a CAGR of 4.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Astellas Pharma, Inc., Eli Lilly and Company, Allergan PLC (AbbVie), Merck Group (Merck Sharp & Dohme Corp.), Boehringer Ingelheim International GmbH, Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Pfizer, Inc., and Abbott Laboratories.
Scope of the Study
Market Segments Covered in the Report:
By Therapy
- Mono Drug Therapy
- Combination Drug Therapy
By Therapeutics Class
- Alpha Blockers
- 5- alpha Reductase Inhibitors
- Phosphodiesterase-5 Inhibitors
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- GlaxoSmithKline PLC (GSK)
- Astellas Pharma, Inc.
- Eli Lilly and Company
- Allergan PLC (AbbVie)
- Merck Group (Merck Sharp & Dohme Corp.)
- Boehringer Ingelheim International GmbH
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Pfizer, Inc.
- Abbott Laboratories
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Benign Prostatic Hyperplasia Therapeutics Market, by Therapy
1.4.2 LAMEA Benign Prostatic Hyperplasia Therapeutics Market, by Therapeutics Class
1.4.3 LAMEA Benign Prostatic Hyperplasia Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapy
3.1 LAMEA Mono Drug Therapy Market by Country
3.2 LAMEA Combination Drug Therapy Market by Country
Chapter 4. LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
4.1 LAMEA Alpha Blockers Market by Country
4.2 LAMEA 5- alpha Reductase Inhibitors Market by Country
4.3 LAMEA Phosphodiesterase-5 Inhibitors Market by Country
4.4 LAMEA Others Market by Country
Chapter 5. LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Country
5.1 Brazil Benign Prostatic Hyperplasia Therapeutics Market
5.1.1 Brazil Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.1.2 Brazil Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.2 Argentina Benign Prostatic Hyperplasia Therapeutics Market
5.2.1 Argentina Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.2.2 Argentina Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.3 UAE Benign Prostatic Hyperplasia Therapeutics Market
5.3.1 UAE Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.3.2 UAE Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.4 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market
5.4.1 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.4.2 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.5 South Africa Benign Prostatic Hyperplasia Therapeutics Market
5.5.1 South Africa Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.5.2 South Africa Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.6 Nigeria Benign Prostatic Hyperplasia Therapeutics Market
5.6.1 Nigeria Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.6.2 Nigeria Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.7 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market
5.7.1 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.7.2 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
Chapter 6. Company Profiles
6.1 GlaxoSmithKline PLC (GSK)
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Astellas Pharma, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Regional Analysis
6.2.4 Research & Development Expense
6.3 Eli Lilly and Company
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expense
6.4 Allergan PLC (AbbVie)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.5 Merck Group (Merck Sharp & Dohme Corp.)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Boehringer Ingelheim International Gmbh
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional & Segmental Analysis
6.6.4 Research & Development Expenses
6.7 Teva Pharmaceutical Industries Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expenses
6.8 Sanofi S.A.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expense
6.9 Pfizer, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.10. Abbott Laboratories
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
TABLE 1 LAMEA Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 2 LAMEA Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 3 LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 4 LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 5 LAMEA Mono Drug Therapy Market by Country, 2017 - 2020, USD Million
TABLE 6 LAMEA Mono Drug Therapy Market by Country, 2021 - 2027, USD Million
TABLE 7 LAMEA Combination Drug Therapy Market by Country, 2017 - 2020, USD Million
TABLE 8 LAMEA Combination Drug Therapy Market by Country, 2021 - 2027, USD Million
TABLE 9 LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 10 LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 11 LAMEA Alpha Blockers Market by Country, 2017 - 2020, USD Million
TABLE 12 LAMEA Alpha Blockers Market by Country, 2021 - 2027, USD Million
TABLE 13 LAMEA 5- alpha Reductase Inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 14 LAMEA 5- alpha Reductase Inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 15 LAMEA Phosphodiesterase-5 Inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 16 LAMEA Phosphodiesterase-5 Inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 17 LAMEA Others Market by Country, 2017 - 2020, USD Million
TABLE 18 LAMEA Others Market by Country, 2021 - 2027, USD Million
TABLE 19 LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Country, 2017 - 2020, USD Million
TABLE 20 LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Country, 2021 - 2027, USD Million
TABLE 21 Brazil Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 22 Brazil Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 23 Brazil Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 24 Brazil Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 25 Brazil Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 26 Brazil Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 27 Argentina Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 28 Argentina Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 29 Argentina Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 30 Argentina Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 31 Argentina Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 32 Argentina Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 33 UAE Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 34 UAE Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 35 UAE Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 36 UAE Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 37 UAE Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 38 UAE Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 39 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 40 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 41 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 42 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 43 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 44 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 45 South Africa Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 46 South Africa Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 47 South Africa Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 48 South Africa Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 49 South Africa Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 50 South Africa Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 51 Nigeria Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 52 Nigeria Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 53 Nigeria Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 54 Nigeria Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 55 Nigeria Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 56 Nigeria Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 57 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 58 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 59 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 60 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 61 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 62 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 63 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 64 key information – Astellas Pharma, Inc.
TABLE 65 Key Information – Eli Lilly and Company
TABLE 66 Key Information – Allergan PLC
TABLE 67 key Information – Merck Group
TABLE 68 Key Information – Boehringer Ingelheim International GmbH
TABLE 69 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 70 Key Information – Sanofi S.A.
TABLE 71 Key Information – Pfizer, Inc.
TABLE 72 Key Information – Abbott Laboratories
List of Figures
FIG 1 Methodology for the research